文献速递前列腺癌

围手术期睾酮能否预测前列腺切除术后基因组风险评分

Does Perioperative Testosterone Predict Post-Prostatectomy Genomic Risk Score?
PubMed 文献 · J Urol · 2022-01-20

本研究纳入2013至2018年接受根治性前列腺切除术且术后病理不良(切缘阳性和/或pT3a及以上)的患者,探讨围手术期血清睾酮水平与基因组风险评分及188个基因表达特征的关系。低睾酮组中位基因组风险评分低于中间及正常睾酮组(0.38 vs 0.52 vs 0.53,p=0.049),三组生化复发无生存差异(p=0.9),低睾酮组接受二次治疗的比值比高于正常组(OR 2.27,95%CI 1.14-4.50,p=0.02)。

要点

  • 低睾酮组中位基因组风险评分低于中间及正常睾酮组(0.38 vs 0.52 vs 0.53,p=0.049)。
  • 三组睾酮水平间生化复发无生存差异(p=0.9)。
  • 低睾酮组接受二次治疗的比值比高于正常睾酮组(OR 2.27,95%CI 1.14-4.50,p=0.02)。

核心结论

  • 本研究首次评估术前睾酮水平与肿瘤转录组的相关性,显示预设基因组风险评分分组与睾酮分组之间无临床相关性。
  • 研究支持内源性睾酮在散发性高危局限性前列腺癌发生中作用有限的观点。

研究设计与样本

  • 纳入2013至2018年接受根治性前列腺切除术且最终手术标本存在不良病理特征(切缘阳性和/或pT3a及以上)的患者。
  • 主要结局为基因组风险评分:低(<0.45)、中间(0.45-0.6)和高(>0.6),并分析血清睾酮水平与188个基于基因表达的特征之间的关联。
  • 次要结局包括生化复发和接受二次治疗。

主要发现

  • 低睾酮组中位基因组风险评分低于中间及正常睾酮组(0.38 vs 0.52 vs 0.53,p=0.049)。
  • 3个睾酮组间生化复发无生存差异(p=0.9)。
  • 低睾酮水平患者接受二次治疗的比值比高于正常水平者(OR 2.27,95%CI 1.14-4.50,p=0.02)。
  • 188个基因表达特征中有43个与睾酮水平相关(p<0.05)。
  • 33个特征与血清睾酮水平呈正相关,其中12个涉及DNA修复通路。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The role of endogenous testosterone in de novo prostate cancer pathogenesis in humans remains unclear. The effect of testosterone on the tumor genome is not explored. We sought to explore the correlation between perioperative testosterone level and genomic risk score in a cohort of men who underwent radical prostatectomy. MATERIALS AND METHODS: We included patients who underwent radical prostatectomy (2013-2018) and had adverse pathological features in their final surgical specimens (positive margin, and/or pT3a or higher). The outcome of interest was the genomic risk score: low (<0.45), intermediate (0.45-0.6) and high (>0.6). The associations between serum testosterone level and 188 gene expression-based signatures were examined. Secondary outcomes of interest included biochemical recurrence and receipt of secondary treatment. RESULTS: The median genomic risk score was lower in the low testosterone group compared to the intermediate and normal testosterone groups (0.38 vs 0.52 vs 0.53, respectively; p=0.049). There was no difference in biochemical recurrence-free survival between the 3 testosterone groups (p=0.9). Patients with low testosterone levels had higher odds of receiving secondary treatment (OR: 2.27; 95% CI: 1.14-4.50; p=0.02) than those with normal levels. A total of 43 (of 188) gene expression signatures were associated with testosterone level (p <0.05). In total, 33 signatures were positively associated with serum testosterone levels, including 12 signatures involved in DNA repair pathways. CONCLUSIONS: This is the first study to assess the correlation of preoperative testosterone level on the tumor transcriptome and showed no clinical correlation between pre-defined genomic risk score groups and testosterone groups. This study adds to the notion of the limited role of endogenous testosterone on the development of de novo high-risk localized prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Shahait M, Cheaib JG, Davicioni E, et al. Does Perioperative Testosterone Predict Post-Prostatectomy Genomic Risk Score? J Urol. 2022. PMID: 35050721. doi:10.1097/JU.0000000000002440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。